Papers
8
Total Citations
195
H-Index
6
About
Dr. Xiaozhi Zhao is a leading urologic surgeon and researcher whose work centers on advancing minimally invasive surgical techniques for prostate, kidney, and adrenal tumors. His most impactful study (96 citations) demonstrated that 68Ga-PSMA-11 PET-CT outperforms mpMRI for preoperative lymph node staging in intermediate- to high-risk prostate cancer, directly influencing clinical staging protocols. Dr. Zhao has pioneered robotic-assisted simple enucleation (RASE) for renal tumors, authoring multiple high-impact papers—including a landmark randomized controlled noninferiority trial (2023) and a propensity-score matched analysis (2018)—that collectively show RASE achieves superior trifecta outcomes (negative margins, minimal complications, preserved renal function) compared to standard partial nephrectomy. His expertise extends to intraoperative ultrasound guidance for endophytic tumors and comparative analyses of laparoscopic versus robotic adrenalectomy approaches. Most recently, he has explored noninvasive therapies, publishing a 2025 trial on electroacupuncture for post-prostatectomy urinary incontinence. With over 190 citations across his core publications, Dr. Zhao’s work consistently refines surgical precision and expands treatment options for urologic cancers.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8